Cover Image
市場調查報告書

關注市場分析:痤瘡

Market Spotlight: Acne

出版商 Datamonitor Healthcare 商品編碼 594578
出版日期 內容資訊 英文 42 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
關注市場分析:痤瘡 Market Spotlight: Acne
出版日期: 2017年10月30日 內容資訊: 英文 42 Pages
簡介

本報告提供痤瘡的治療藥市場相關分析,疾病概要和患者數的變化、預測,目前的主要的治療方法,法規環境和近幾年主要的事件,現在開發中臨床實驗的進展與上市計劃,主要的治療藥的市場趨勢預測 (今後10年份),資本交易的動向等調查。

分析的要點

疾病的背景情況

治療方法

  • 局部治療
  • 全身治療
  • 物理治療

流行病學

已上市醫藥品

  • 各國的認證情形

開發平台上的醫藥品

將產生的主要事件

法規相關的主要事件 (共2件)

授權合約、資產收購交易 (1件)

母體專利

商機

臨床實驗形勢

  • 贊助商數:各狀態
  • 贊助商數:各相位
  • 主要企業的主要趨勢 (共2件)

相關分析

  • 處方藥的資訊

附錄

目錄
Product Code: DMKC0181187

This Market Spotlight report covers the Acne market, comprising key pipeline and marketed drugs, clinical trials, upcoming and regulatory events, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.recasts.

Key Takeaways:

  • Datamonitor Healthcare estimates that in 2016, there were approximately 615 million prevalent cases of acne worldwide, and forecasts that number to increase to 673 million prevalent cases by 2025. Approved drugs in the acne space target retinoic acid receptor, bacterial ribosome, bacterial protein synthesis, dihydropteroate synthetase, steroid 5a-reductase, estrogen receptor alpha, estrogen receptor beta, folate receptor, mineralocorticoid receptor, and progesterone receptor. These are commonly administered via the oral and topical routes.
  • The majority of industry-sponsored drugs in active clinical development for acne are in Phase II. Therapies in mid-to-late-stage development for acne focus on a variety of targets. The majority of the drugs in mid-to-late-stage development for acne are administered via the topical route, with the remainder being oral, subcutaneous and intravenous.
  • High impact upcoming events for drugs in the acne space include topline Phase II and Phase III trial results. There were 21 licensing and asset acquisition activities involving acne drugs during 2012-17, seven of which occurred in 2014. The $50m license agreement between Actavis (now Allergan) and Mayne Pharma, pursuant to which Actavis will divest the US rights to Doryx brand acne treatment and related assets to Mayne, was the largest deal during the 201217 period.
  • Yaz's sales ranked highest among drugs available for acne during 2012-16. The clinical trials distribution across Phase I-IV indicates that the majority of trials for acne have been in late phases of development, with 55% of trials in Phase III-IV, and 45% in Phase I-III.
  • The US has a substantial lead in the number of acne clinical trials globally. Germany leads the major EU markets, while Japan has the top spot in Asia.
  • GlaxoSmithKline has the highest number of completed clinical trials for acne

TABLE OF CONTENTS

KEY TAKEAWAYS

DISEASE BACKGROUND

TREATMENT

  • Topical therapy
  • Systemic therapy
  • Physical treatments

EPIDEMIOLOGY

MARKETED DRUGS

  • Approvals by country

PIPELINE DRUGS

KEY UPCOMING EVENTS

KEY REGULATORY EVENTS

  • Galderma Pioneers NDA Path Into OTC Acne Treatment Market
  • Indian Start-up Vyome Wins Milestone FDA Nod For Acne Studies

LICENSING AND ASSET ACQUISITION DEALS

  • Sato licenses Japanese rights to Novan's acne candidate SB204

PARENT PATENTS

REVENUE OPPORTUNITY

CLINICAL TRIAL LANDSCAPE

  • Sponsors by status
  • Sponsors by phase
  • Acne Pipeline Yields Three Disappointments, One Win So Far In 2017
  • Xenon Down On Novel Acne Treatment Failure

BIBLIOGRAPHY

  • Prescription information:

APPENDIX

LIST OF FIGURES

  • Figure 1: Trends in prevalent cases of acne, 2016-25
  • Figure 2: Pipeline drugs for acne in the US
  • Figure 3: Pipeline drugs for acne, by country
  • Figure 4: Pipeline drugs for acne, by drug type
  • Figure 5: Pipeline drugs for acne, by classifications
  • Figure 6: Key upcoming events in acne
  • Figure 7: Licensing and asset acquisition deals in acne
  • Figure 8: Parent patents in acne
  • Figure 9: Clinical trials in acne
  • Figure 10: Top 10 drugs for clinical trials in acne
  • Figure 11: Top 10 companies for clinical trials in acne
  • Figure 12: Trial locations in acne
  • Figure 13: Acne trials sponsors, by status
  • Figure 14: Acne trials sponsors, by phase

LIST OF TABLES

  • Table 1: Prevalent cases of acne, 2016-25
  • Table 2: Marketed drugs for acne
  • Table 3: Approvals by country for acne
  • Table 4: Pipeline drugs for acne in the US
  • Table 5: Historical global sales, by drug ($m), 2012-16
  • Table 6: Forecasted global sales, by drug ($m), 2017-22
Back to Top